Document:

Form of Lock-up Agreements

 Exhibit 10.6 
    
 Form of Lock-up Agreement for 
 Directors and Officers pursuant to Section 5(i) 
  
 FTN MIDWEST SECURITIES CORP. 
     as Representative of the several Underwriters 
 350 Madison Avenue, 20th Floor

 New York, New York 10017 
  

	 	Re:	Proposed Public Offering by Healthcare Acquisition Partners Corp. 

  
 Dear Sirs: 
  The undersigned, an officer and/or director
of Healthcare Acquisition Partners Corp., a Delaware corporation (the “Company”), and the owner of              shares of common stock (the “Shares”) of the
Company, understands that FTN Midwest Securities Corp. (the “Representative”), proposes to enter into an Underwriting Agreement with the Company with respect to the proposed consummation of a public offering of shares common stock, $.0001
par value, of the Company (the “Common Stock”). In recognition of the benefit that such an offering will confer upon the undersigned as the owner of the Shares and an officer and/or director of the Company, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Representative that, during a period of 180 days from the date of the consummation of an acquisition by the Company conforming to the
requirements set forth in the registration statement on Form S-1 filed on October 14, 2005, as amended (the “Registration Statement”), by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended
(the “Act”), the undersigned will not, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of,
or otherwise dispose of or transfer any shares of Common Stock, or any securities convertible into or exchangeable or exercisable for shares of Common Stock, whether now owned or hereafter acquired (including, without limitation, any issued but not
outstanding shares of Common Stock held in treasury by the Company) by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition, or file, or cause to be filed, any registration statement under the
Act with respect to any of the foregoing (collectively, the “Lock-Up Securities”) or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic
consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of shares of Common Stock, options to purchase Common Stock or other securities, in cash or otherwise. 
  
 The foregoing sentence shall not apply to the undersigned and other persons
executing agreements substantially similar to this agreement transferring Lock-Up Securities to the Company. If the undersigned is an affiliate of the Representative, then the undersigned cannot be released from its obligations under this agreement
by the Representative prior to its expiration without the express, written consent of the Company. 
   
    

			
	 Very truly yours,

		
	 Signature:
	 	 
		
	 Print Name:
	 	 

  

 2 

  
 Form of Lock-up Agreement for

 FTN Midwest Securities Corp., pursuant to Section 5(i) 
  
 Healthcare Acquisition Partners Corp. 
 350
Madison Avenue 
 New York, NY 10017 
  

	 	Re:	Proposed Public Offering by Healthcare Acquisition Partners Corp. 

  
 Dear Sirs: 
  
 The undersigned, the holder of an option to purchase certain shares of common stock of Healthcare Acquisition Partners Corp., a Delaware corporation (the “Company”), understands that the Company proposes to
consummate a public offering (the “IPO”) of shares common stock, $.0001 par value, of the Company (“the Common Stock”). In recognition of the benefit that such an offering will confer upon the undersigned as a optionholder of the
Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Company that, during a period of 180 days from the date of the consummation of the IPO, the
undersigned will not, without the prior written consent of the Company, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant for the sale of, or otherwise dispose of or transfer any shares of Common Stock, or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with
respect to which the undersigned has or hereafter acquires the power of disposition, or file, or cause to be filed, any registration statement under the Securities Act of 1933, as amended, with respect to any of the foregoing (collectively, the
“Lock-Up Securities”) or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such
swap or transaction is to be settled by delivery of Common Stock, options to purchase Common Stock or other securities, in cash or otherwise. 
  

			
	 Very truly yours,

	
	FTN MIDWEST SECURITIES CORP.
		
	 By:
	 	 
	 Name:
	 	 
	 Title:Form of Letter Agreement - members of management

 Exhibit 10.9 
  
 [FORM OF LETTER AGREEMENT TO BE ENTERED INTO BY AND BETWEEN THE 
 REGISTRANT AND MEMBERS OF MANAGEMENT OTHER THAN THE INITIAL 
 STOCKHOLDERS] 

 
                     ,
2006                     
  
 HEALTHCARE ACQUISITION PARTNERS CORP. 
 350 Madison Avenue 
 New York, NY 10017 
  
 Re: Healthcare Acquisition Partners Corp. Initial Public Offering –
Letter Agreement 
  
 Dear Ladies and Gentlemen:

  
 This letter is being delivered to you in accordance with the
Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Healthcare Acquisition Partners Corp., a Delaware corporation (the “Company”), and FTN Midwest Securities Corp., as
Representative (the “Representative”) of the Underwriters named in Schedule I thereto (the “Underwriters”), relating to an underwritten initial public offering (the “IPO”) of
the Company’s units (the “Units”), each comprised of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and two warrants, each being exercisable for
one share of Common Stock (each, a “Warrant”). The capitalized terms set forth on Schedule 1 attached hereto are hereby incorporated by reference herein. 
  
 In order to induce the Company and the Underwriters to enter into the Underwriting Agreement and to proceed with the IPO and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees with the Company as follows: 
  
 1. The undersigned agrees not to acquire any IPO Shares prior to the completion of a Business Combination. 
  
 2. The undersigned represents and warrants that (i) the biographical information
furnished to the Company and the Representative and attached hereto as Exhibit A is true and accurate in all respects (other than de minimis errors or omissions), does not omit any material information with respect to the undersigned’s
background during the previous five years and contains all of the information required to be disclosed pursuant to Item 401 of Regulation S-K, promulgated under the Securities Act of 1933, as amended, (ii) the questionnaires furnished by
the undersigned to the Company and the Representative are true and accurate in all respects (other than de minimis errors or omissions), and (ii) the undersigned has full right and power, without violating any agreement by which the undersigned
is bound, to enter into this letter agreement and to serve as [              ] [and] [a member of the Board of Directors] of the Company. The undersigned further
represents and warrants that: 
  
 (a) The undersigned is
not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction; 

 (b) The undersigned has never been convicted of or pleaded guilty to any crime (i) involving
any fraud or (ii) relating to any financial transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities and such person is not currently a defendant in any such criminal proceeding; and

  
 (c) The undersigned has never been suspended or
expelled from membership in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended or revoked. 
  
 The undersigned acknowledges and understands that the Underwriters and the Company will rely upon the agreements,
representations and warranties set forth herein in proceeding with the IPO. 
  
 This letter agreement shall be binding on the undersigned and such person’s respective successors, heirs, personal representatives and assigns. This letter agreement shall terminate on the earlier of (i) the
Business Combination Date and (ii) the Termination Date. 
  
 This letter agreement shall be governed by and interpreted and construed in accordance with the laws of the State of New York applicable to contracts formed and to be performed entirely within the State of New York, without regard to the
conflicts of law provisions thereof to the extent such principles or rules would require or permit the application of the laws of another jurisdiction. 
  
 No term or provision of this letter agreement may be amended, changed, waived, altered or modified except by written instrument executed and delivered by
the party against whom such amendment, change, waiver, alteration or modification is to be enforced. 
  
 [The Remainder of this Page is Intentionally Left Blank] 
  

 2 

	
	Sincerely,
	  

  

			
	 Accepted and agreed:
  

	 HEALTHCARE ACQUISITION PARTNERS CORP.
  

	By:	 	  

	Name:	 	 
	Title:	 	 

 Schedule 1 
  

SUPPLEMENTAL COMMON DEFINITIONS 
  
 Unless the context shall otherwise require, the following terms shall have the following respective meanings for all purposes, and the following
definitions are equally applicable to both the singular and the plural forms and the feminine, masculine and neuter forms of the terms defined. 
  
 “Business Combination” shall mean the acquisition by the Company, whether by merger, capital stock exchange, asset acquisition or other
similar type of combination, of one or more operating businesses in the healthcare-related sector, having, collectively, a fair market value (as calculated in accordance with the Company’s Amended and Restated Certificate of Incorporation) of
at least 80% of the Company’s net assets at the time of such merger, capital stock exchange, asset acquisition or other similar type of combination. 
  
 “Business Combination Date” shall mean the date upon which a Business Combination is consummated. 
  
 “Effective Date” shall mean the date upon which the
Registration Statement is declared effective under the Securities Act of 1933, as amended, by the SEC. 
  
 “IPO Shares” shall mean all shares of Common Stock issued by the Company in its IPO, regardless of whether such shares were issued to an
Insider or otherwise. 
  
 “Prospectus” shall mean
the final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and included in the Registration Statement. 
  
 “Registration Statement” shall mean the registration statement filed by the Company on Form S-1 (No. 333-129035) with the SEC on
October 14, 2005, and any amendment or supplement thereto, in connection with the Company’s IPO. 
  
 “SEC” shall mean the United States Securities and Exchange Commission. 
  
 “Termination Date” shall mean the date that is sixty (60) calendar days immediately following the
Transaction Failure Date (inclusive thereof). 
  
 “Transaction Failure” shall mean the earlier of (i) the failure to enter into a definitive agreement with respect to a Business Combination on any day during the eighteen-month period immediately following the
Effective Date, and (ii) the failure to consummate a Business Combination on any day during the twenty four-month period immediately following the Effective Date. 

 “Transaction Failure Date” shall mean the date upon which a Transaction Failure occurs,
as conclusively established by a majority of the Independent Directors of the Company immediately following a Transaction Failure. 
  

 5 

 Exhibit A 
  

BIOGRAPHY 
  
 [Insert Bio here] 
  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]